Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies

J. Chalmers (Dundee (Angus), United Kingdom), D. Cipolla (Hayword, United States of America), B. Thompson (Owings Mills, United States of America), A. Davis (Clayton, United States of America), A. O'Donnell (Washington, United States of America), G. Tino (Philadelphia, United States of America), I. Gonda (Hayward, United States of America), C. Haworth (Cambridge, United Kingdom), J. Froehlich (Hayward, United States of America)

Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Session: ALERT: Infection in adults and children
Session type: Clinical trials session
Number: 4136
Disease area: Airway diseases, Paediatric lung diseases, Respiratory infections

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Chalmers (Dundee (Angus), United Kingdom), D. Cipolla (Hayword, United States of America), B. Thompson (Owings Mills, United States of America), A. Davis (Clayton, United States of America), A. O'Donnell (Washington, United States of America), G. Tino (Philadelphia, United States of America), I. Gonda (Hayward, United States of America), C. Haworth (Cambridge, United Kingdom), J. Froehlich (Hayward, United States of America). Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies. 4136

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: